Dr. Ari J Green is the Chief of the Division of Neuroimmunology and Glial Biology in the Department of Neurology at the University of California at San Francisco. His team consists of more than 20 laboratories and groups dedicated to discovering the causes of Multiple Sclerosis and related disorders; and to developing treatments as well as cures for these conditions. Dr. Green is also Medical Director of the UCSF MS and Neuroinflammation Center – one of the largest clinics of its kind in the United States with a broad focus on caring for patients with conditions in which immune dysregulation or inflammation play an important role. The clinic seeks to provide comprehensive, patient-centered care for people living with these diseases with a wide variety of ancillary services for diagnosis, monitoring and supporting patients and their families. Dr. Green’s laboratory is dedicated to the biological validation of potential biomarkers intended to measure remyelination and repair (as well as progression) in MS as a means to accelerate clinical trials for reparative treatments. His major scientific contributions include directing the first successful phase II clinical trial of a remyelinating agent for MS, developing methods for monitoring myelin repair, detailing the histopathological changes in the retina seen in MS, and describing the role of progranulin in the retina along with discovering a previously unknown retinal phenotype in progranulin-related frontotemporal dementia. His lab maintains an active interest in the developing and validating biomarkers for neurodegenerative disease generally and inflammatory diseases of the central nervous system in particular. He also co-directs the Program in Remyelination and Repair with Dr. Jonah Chan as well as the Neurodiagnostics Center in the Department of Neurology.
Dr. Green completed medical school at Duke University School of Medicine in 2001 (during which time he had a Howard Hughes Medical Institute predoctoral fellowship with Drs. Jorge Oksenberg and Stephen L Hauser) and Internship in the Department of Medicine at UCSF in 2002. He completed Residency training at UCSF including Chief Residency in Neurology and post residency fellowships in Neuroimmunology under Dr. Stephen Hauser and Neuro-ophthalmology under Drs. William F. Hoyt and Kimberly Cockerham at UCSF. He then had a visiting fellowship at Queen’s University Belfast under Dame Ingrid Allen in Neuropathology. He was named the first AAN/NMSS Clinician Science Fellow in 2005 and received a Howard Hughes Clinician Scientist award from HHMI. He was named as the Debbie and Andy Rachleff Distinguished Professor of Neurology in 2009 and joined the Department of Ophthalmology at UCSF in 2011. He was a Harry Weaver Neuroscience Scholar and has served as Associate Editor for JAMA Neurology since 2017.
The Division of Neuroimmunology and Glial Biology - since its inception under the leadership of Dr. Stephen Hauser in 1992 - has made major contributions to all aspects of the biology of MS and its treatment including defining the full genetic risk profile for MS, discovering the importance of B cell biology in MS, improving our understanding of adaptive immune processes in inflammatory diseases of the brain and making groundbreaking discoveries in therapeutics for repair and remyelination in MS and other demyelinating diseases. The group continues to be focused on breakthrough developments in the field including microbiome research, glial biology work, and working to uncover the triggers of MS and other inflammatory diseases of the CNS. Under Dr. Green’s leadership, the group has expanded its focus to investigate new methods for understanding infectious and inflammatory diseases of the brain as well as developmental and autoimmune disorders of the CNS that lead to neurological disability. The Division is also a leading force for the education of trainees in clinical care, scientific disciplines and graduate studies in all areas related to our clinical and research mission. We actively train clinical fellows, residents, students and community members in issues of importance to our patients and their families.